Aclaris Therapeutics announced that its Phase 2 ADMIRATION trial of bosakitug (ATI-045) for moderate-to-severe atopic dermatitis failed to meet its primary and secondary endpoints. Despite robust target engagement and biomarker downregulation, the company will shift focus toward its oral ITK inhibitors and bispecific antibody ATI-052. The company also announced the initiation of a Phase 2b trial for modzatinib in lichen planus and plans to file an IND for ATI-9494 in Q4 2026.
Aclaris Therapeutics reported a net loss of $59.8 million for the nine months ended September 30, 2026, compared to $45.1 million for the same period in 2025. The company significantly increased its cash position through at-the-market sales of common stock, raising approximately $116.2 million in net proceeds during the first nine months of 2026.
Aclaris Therapeutics reported its Q3 2026 financial results, highlighting a cash position of $156.4M which is expected to fund operations through the first half of 2029. The company also provided clinical updates, including positive Phase 1b data for ATI-052 in atopic dermatitis and asthma, and the planned initiation of a Phase 2b trial for modzatinib in the fourth quarter of 2026.
Term
Q3 2026
“Aclaris is developing unique product candidates designed to provide improved therapeutic options across a variety of inflammatory disorders with the goal of raising the efficacy ceiling, and our recent progress reflects continued execution toward that objective.”
Dr. Neal Walker, Chief Executive Officer and Chair of the Board of Directors of Aclaris
Aclaris Therapeutics entered into an underwriting agreement to sell 7,785,714 shares of common stock and pre-funded warrants for 6,500,000 shares at a price of $3.50 per share. The company expects to receive gross proceeds of approximately $50 million ($46.7 million net) to fund its operations. The offering is expected to close on October 28, 2026.
Aclaris Therapeutics announced positive Phase 1b proof-of-concept results for ATI-052, a bispecific antibody targeting TSLP and IL-4Rα, in patients with atopic dermatitis and asthma. The data showed a 45% placebo-adjusted mean improvement in EASI scores for atopic dermatitis and rapid improvements in lung function for asthma patients, with a favorable safety profile and no observed conjunctivitis. The company plans to prioritize Phase 2b development of ATI-052 for eosinophilic esophagitis (EoE) starting in early 2027.